Emily Chan
Faculty Member
Last active: 3/28/2014

  1. Timing versus duration of adjuvant therapy for pancreatic cancer: all the lessons we need in life are taught to us as children. Chan E, Berlin J (2014) J Clin Oncol 32(6): 487-8
    › Primary publication · 24419124 (PubMed)
  2. Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. Cardin DB, Goff L, Li CI, Shyr Y, Winkler C, DeVore R, Schlabach L, Holloway M, McClanahan P, Meyer K, Grigorieva J, Berlin J, Chan E (2014) Cancer Med 3(3): 572-9
    › Primary publication · 24574334 (PubMed) · PMC4101748 (PubMed Central)
  3. Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Huang J, Nair SG, Mahoney MR, Nelson GD, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Thibodeau SN, Smyrk TC, Grothey A, Sinicrope FA, Webb TA, Farr GH, Pockaj BA, Berenberg JL, Mooney M, Sargent DJ, Alberts SR, Alliance for Clinical Trials in Oncology (2014) Clin Colorectal Cancer 13(2): 100-9
    › Primary publication · 24512953 (PubMed) · PMC4019685 (PubMed Central)
  4. Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors. Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris HA, Zamboni WC (2013) Eur J Clin Pharmacol 69(12): 2073-81
    › Primary publication · 23989300 (PubMed)
  5. Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma. Goyal L, Supko JG, Berlin J, Blaszkowsky LS, Carpenter A, Heuman DM, Hilderbrand SL, Stuart KE, Cotler S, Senzer NN, Chan E, Berg CL, Clark JW, Hezel AF, Ryan DP, Zhu AX (2013) Cancer Chemother Pharmacol 72(6): 1305-14
    › Primary publication · 24121453 (PubMed)
  6. Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. Abramson RG, Abramson VG, Chan E, Horn L, Keedy VL, Pao W, Sosman JA (2013) AJR Am J Roentgenol 200(3): 475-83
    › Primary publication · 23436834 (PubMed) · PMC3652983 (PubMed Central)
  7. Aflibercept. Ciombor KK, Berlin J, Chan E (2013) Clin Cancer Res 19(8): 1920-5
    › Primary publication · 23444216 (PubMed) · PMC3710732 (PubMed Central)
  8. Controversies in radiation for upper rectal cancers. Chan E, Wise PE, Chakravarthy AB (2012) J Natl Compr Canc Netw 10(12): 1567-72
    › Primary publication · 23221791 (PubMed)
  9. Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer. Chan E, Lafleur B, Rothenberg ML, Merchant N, Lockhart AC, Trivedi B, Chung CH, Coffey RJ, Berlin JD (2011) Am J Clin Oncol 34(6): 581-6
    › Primary publication · 21217396 (PubMed) · PMC3133812 (PubMed Central)
  10. Advances in oncology. Panitumumab and combination chemotherapy in first- and second-line therapy for colorectal cancer. Chan E (2010) Clin Adv Hematol Oncol 8(1): 37-9
    › Primary publication · 20351681 (PubMed)